Somatostatin agonists
View Patent ↗The present invention is directed to cyclic peptides of formula (I): X-A 1 -cyclo(D-Cys-A 3 -A 4 -Lys-A 6 -A 7 )-A 8 -Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors. The peptides are useful for treating a variety of diseases, including Cushings Syndrome, gonadotropinoma, hyperparathyroidism, Paget's disease, VIPoma, nesidioblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea related to AIDS and other conditions, irritable bowel syndrome, pancreatitis, Crohn's Disease, systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks, sclerodoma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Graves' Disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocysts, pancreatic ascites, leukemia, meningioma, cancer cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, inhibiting the accelerated growth of a solid tumor, decreasing body weight, treating insulin resistance, Syndrome X, prolonging the survival of pancreatic cells, fibrosis, hyperlipidemia, hyperamylinemia, hyperprolactinemia and prolactinemia.
1. A method of eliciting a somatostatin agonist response in a human or other animal in need thereof, which comprises administering an effective amount of a peptide of formula (I)
X-A 1 -cyclo(D-Cys-A 3 -A 4 -Lys-A 6 -A 7 )-A 8 -Y, (I)
or a pharmaceutically acceptable salt thereof,
wherein
A 1 and A 3 are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;
A 4 is L-Trp, D-Trp, L-β-methyl-Trp or D-β-methyl-Trp;
A 6 is —NH—(CHR 1 ) n —CO—, where n is 2, 3, or 4;
A 7 is L- or D-Cys;
A 8 is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;
Y is NR 2 R 3 where R 2 and R 3 are each independently H or (C 1 -C 5 )alkyl;
R 1 is selected from the group consisting H, (C 1 -C 4 )alkyl and —CH 2 -aryl; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, aryl, aryl(C 1-6 )alkyl, (C 1-6 )alkoxy, —N(R 4 R 5 ), —COOH, —CON(R 4 R 5 ), halo, —OH, —CN, and —NO 2 ;
R 4 and R 5 each is, independently for each occurrence, H or (C 1-3 )alkyl;
where the Cys of A 2 is bonded to the Cys of A 7 by a di-sulfide bond formed from the thiol groups of each Cys,
to the human or other animal.
2. A method of inhibiting the secretion of growth hormone, insulin, glucagon or pancreatic exocrine secretion in a human or other animal in need thereof, which comprises administering a peptide of formula (I)
X-A 1 -cyclo(D-Cys-A 3 -A 4 -Lys-A 6 -A 7 )-A 8 -Y, (I)
or a pharmaceutically acceptable salt thereof,
wherein
A 1 and A 3 are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;
A 4 is L-Trp, D-Trp, L-β-methyl-Trp or D-β-methyl-Trp;
A 6 is —NH—(CHR 1 ) n —CO—, where n is 2, 3, or 4;
A 7 is L- or D-Cys;
A 8 is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;
Y is NR 2 R 3 where R 2 and R 3 are each independently H or (C 1 -C 5 )alkyl;
R 1 is selected from the group consisting H, (C 1 -C 4 )alkyl and —CH 2 -aryl; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, aryl, aryl(C 1-6 )alkyl, (C 1-6 )alkoxy, —N(R 4 R 5 ), —COOH, —CON(R 4 R 5 ), halo, —OH, —CN, and —NO 2 ;
R 4 and R 5 each is, independently for each occurrence, H or (C 1-3 )alkyl;
where the Cys of A 2 is bonded to the Cys of A 7 by a di-sulfide bond formed from the thiol groups of each Cys,
to said human or other animal.
3. The method according to claim 1 or 2 , wherein said peptide of formula (I) is a peptide wherein
A 1 is L-Phe, D-Phe, L-Cpa or D-Cpa;
A 3 is L-Tyr, L-Trp or L-3-Pal;
A 4 is D-Trp;
A 6 is β-Ala or Gaba;
A 7 is L-Cys;
A 8 is L-Thr, L-Trp, L-Leu or L-Nal; and
R 2 and R 3 are each H;
or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 or 2 , wherein said peptide is of the formula
Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH 2 ;
Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-β-Ala-Cys)-Nal-NH 2 ;
Phe-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH 2 ;
Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Nal-NH 2 ;
Phe-cyclo(D-Cys-Trp-D-Trp-Lys-Gaba-Cys)-Nal-NH 2 ;
Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Trp-NH 2 ;
D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)Nal-NH 2 ;
D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Leu-NH 2 ; or
Phe-cyclo-(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Thr-NH 2 ;
or a pharmaceutically acceptable salt thereof.
5. The method according to claim 1 or 2 , wherein said peptide is of the formula
Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH 2 ; or
Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-β-Ala-Cys)-Nal-NH 2 ;
or a pharmaceutically acceptable salt thereof.
6. The method according to claim 1 or 2 , wherein said peptide or pharmaceutically acceptable salt thereof is in the form of a pharmaceutical composition which comprises an effective amount of a peptide of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.